Clinical trials: Gene Mutation
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor
- Trial name
- NCT04161391
- Testing
- TPX-0046
- Where
- 21 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Turning Point Therapeutics, Inc.
Breast Cancer
Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors
Exercise training has beneficial effects in cancer survivors to minimize some of the side effects of cancer and its treatment and improve long-term prognosis, but there are numerous hurdles for individuals diagnosed with, and…
- Trial name
- NCT02739620
- Testing
- Neuromuscular electrical stimulation
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Vermont
Chronic Stroke, Healthy Aging
Alternative Therapies for Improving Motor Impairment, Fall-risk and Overall Physical Function
Neurological impairment such as stroke and aging is a leading cause of adult disability. Traditional rehabilitative therapies can help regain motor function and ameliorate disability.
- Trial name
- NCT03758846
- Testing
- Cognitive-motor exergaming, Conventional balance Training, Dance Therapy for Stroke
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Melanoma (Skin Cancer)
A Comparative Usability Study of Two Total Body Skin Imaging Systems
This study aims to generate evidence on patient and dermatologist perspectives regarding two total body photography systems. Patient and clinician preferences represent key factors in healthcare decision-making.
- Trial name
- NCT07740642
- Testing
- Deviskan, Vectra WB360, Standard-of-care clinical examinations
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University Hospital, Basel, Switzerland
Malignant Melanoma
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansion study of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with vemurafenib or vemurafenib plus cobimetinib in…
- Trial name
- NCT01656642
- Testing
- Atezolizumab, Cobimetinib, Vemurafenib
- Where
- 8 sites in United States
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
NSCLC, Leptomeningeal Metastasis
Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis
A prospective, open-label, multi-center, single-arm study of Almonertinib combined With Bevacizumab for EGFR-mutant NSCLC patients with leptomeningeal metastasis.
- Conditions
- NSCLC, Leptomeningeal Metastasis, EGFR Activating Mutation
- Trial name
- ATTRACT (NCT04944069)
- Testing
- Almonertinib, Bevacizumab
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Non-Small Cell Lung Cancer
Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients
The main objective of this study is to evaluate the safety and tolerability of BPI-15086.
- Trial name
- NCT02914990
- Testing
- BPI-15086
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Sensorineural Hearing Loss, Bilateral
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
Part A of this trial evaluated the safety and tolerability of a single surgical administration procedure in one or both ear(s) with one of two dose levels of AAVAnc80-hOTOF (LY888891) and evaluated the Akouos Delivery Device…
- Trial name
- NCT05821959
- Testing
- AAVAnc80-hOTOF via Akouos Delivery Device, AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor, NSCLC
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.
- Conditions
- Advanced Solid Tumor, NSCLC, CRC
- Trial name
- NCT05002270
- Testing
- JAB-21822 (KRAS G12C inhibitor), Cetuximab (EGFR inhibitor)
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Epithelial Ovarian Cancer, Homologous Recombination Deficiency
HRD and Resistance to PAPPi in EOC Patients
The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients has been investigated in previous studies (NCT04190667…
- Conditions
- Epithelial Ovarian Cancer, Homologous Recombination Deficiency, Homologous Recombination Repair Gene Mutation, Poly(ADP-ribose) Polymerase Inhibitor
- Trial name
- NCT05310370
- Testing
- Testing of homologous recombination deficiency
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Lei Li
Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression
JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis
This study included 76 newly diagnosed RA patients and 50 matched controls. Basal JAK2 mutation was assessed by PCR in blood samples, TNF-α and IL 6 were measured by ELISA in serum of patients and controls.
- Trial name
- NCT04667988
- Testing
- JAK expression
- Where
- Egypt
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Changes in Macular Pigment Optical Density
Regional Kale as Source of Lutein and Zeaxanthin to Improve Vision of AMD-patients
The age-related macular degeneration (AMD) is an age-dependent, multi-factorial disease. In Western industrial countries, it is the main cause of visual impairments. In Germany, approximately 4.5 million people suffer from AMD.
- Trial name
- KALESIGHT (NCT02136303)
- Testing
- S1: Dosage-dependency, S2: Kale extract versus kale purée, S3: Kale extract: AMD-patients
- Where
- Germany
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Jena
Non Small Cell Lung Cancer, EGFR T790M
Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation
Liquid biopsy plays a pivotal role in cancer therapeutics, encompassing critical applications such as early cancer detection, disease progression monitoring, and tailored treatment plan formulation, heralded as a pivotal avenue…
- Trial name
- NCT06573073
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- LifeOS Genomics Corporation
Neoplasms, Breast
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast cancer (Independent of hormone receptor [HR] status, including HR positive [+] and…
- Trial name
- ZEST (NCT04915755)
- Testing
- Niraparib
- Where
- 198 sites in United States, Argentina and 25 more
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer
Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors
The aim of the COMBINATION trial is to prospectively study the sequential approach of using afatinib combined with a short course of chemotherapy, followed by osimertinib, upon progression and acquisition of a T790M mutation…
- Trial name
- COMBINATION (NCT05298176)
- Testing
- Afatinib, Osimertinib, Carboplatin and Pemetrexed
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Amsterdam UMC, location VUmc
Melanoma
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
This was a two-arm, double-blinded, randomized, Phase III study comparing dabrafenib and trametinib combination therapy to dabrafenib administered with a placebo (dabrafenib monotherapy).
- Trial name
- NCT01584648
- Testing
- Dabrafenib, Trametinib
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 423 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC)
PROREPAIR is a prospective multicenter observational cohort study of unselected patients with metastatic Castration Resistant Prostate Cancer (mCRPC) with unknown germline mutational status at study entry and who are candidates…
- Trial name
- NCT03075735
- Volunteers
- 408 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML induction and consolidation therapy.
- Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD)
- Trial name
- NCT02632708
- Testing
- AG-120, AG-221, cytarabine
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 153 people
- Sponsor
- Institut de Recherches Internationales Servier
Prostate Cancer
Race-related Alternative Splicing: Novel Targets in Prostate Cancer
Data from evaluating prostate cancer (PCa) biopsy tissue from AA and white patients has led to the discovery of alternative splicing as a novel molecular mechanism underlying more aggressive PCa in AA men.
- Trial name
- PCaP splicing (NCT03424213)
- Testing
- No interventions - retrospective data collection
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Duke University
Non-Small Cell Lung Cancer, EGFR Mutation
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer
Protocol Title A Study to Evaluate ANS014004 in Combination with EGFR-TKI in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer The main purpose of this research study is to Find a safe…
- Conditions
- Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
- Trial name
- NCT07285148
- Testing
- ANS014004 + PLB1004, ANS014004 + Osimertinib
- Where
- United States
- Volunteers
- 253 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.